Immunoglobulin News and Research RSS Feed - Immunoglobulin News and Research

Simple method to purify cashew allergens could help scientists better understand allergic reactions

Simple method to purify cashew allergens could help scientists better understand allergic reactions

It's well known that peanuts can cause severe reactions in people who are allergic, but research suggests that the risk of developing a life-threatening reaction could be higher for those allergic to cashews. Now scientists have come up with a fast and simple method to purify the three main cashew allergens to help better grasp how they work and their effects on people. [More]
Study shows clear role of bacteria in modulating immune function in the lungs

Study shows clear role of bacteria in modulating immune function in the lungs

Microbiota--the trillions of bacteria that co-exist in the body--regulate the ability of lung dendritic cells to generate immune responses, according to a study led by researchers from the Icahn School of Medicine at Mount Sinai, published online in the Journal of Experimental Medicine. [More]
Acute bulbar palsy variant of Guillain-Barré syndrome found

Acute bulbar palsy variant of Guillain-Barré syndrome found

Researchers have identified a new variant form of Guillain-Barré syndrome that is characterised by prominent acute bulbar palsy without neck or limb weakness. [More]
Lower levels of antibodies in saliva linked to increased risk of mortality

Lower levels of antibodies in saliva linked to increased risk of mortality

New research from the University of Birmingham has found that lower levels of antibodies in saliva are associated with of an elevated risk of mortality, and could be an early indicator of risk. [More]
Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV-infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. [More]
Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus. [More]
CytoSorbents partners with Hoang Long Pharma to bring CytoSorb to Vietnam

CytoSorbents partners with Hoang Long Pharma to bring CytoSorb to Vietnam

CytoSorbents Corporation, a leader in critical care immunotherapy commercializing its CytoSorb extracorporeal cytokine adsorber to control deadly inflammation using blood purification, today announced an exclusive multi-year distribution agreement with Hoang Long Pharma, a medical distributor in Vietnam specializing in the distribution of innovative pharmaceuticals, biologics, and devices to treat patients suffering from critical illnesses, immunologic disorders and deficiencies, and infections. [More]
New framework launched for global elimination of human rabies

New framework launched for global elimination of human rabies

A new framework to eliminate human rabies and save tens of thousands of lives each year has been launched today by the World Health Organization, the World Organization for Animal Health, the Food and Agriculture Organization of the United Nations and the Global Alliance for the Control of Rabies. [More]
Green Cross' Biologics License Application for IVIG-SN submitted to FDA

Green Cross' Biologics License Application for IVIG-SN submitted to FDA

Green Cross Corporation, a South Korean biopharmaceutical company, today announced that it has submitted its Biologics License Application for IVIG-SN (human normal immunoglobulin G for intravenous administration) to the United States Food and Drug Administration. [More]
Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis. The group began at Northwestern University, Chicago, under the direction of Dr. David McPherson and he continues to lead the group. [More]
Hiroshima University researchers report promising new avenue for treating hepatitis B

Hiroshima University researchers report promising new avenue for treating hepatitis B

A promising new avenue for treating hepatitis B has been reported by researchers at Hiroshima University who have developed a new animal model of the disease. [More]
Research provides leads for new strategies to develop HIV vaccine

Research provides leads for new strategies to develop HIV vaccine

Recent research has yielded new information about immune responses associated with--and potentially responsible for--protection from HIV infection, providing leads for new strategies to develop an HIV vaccine. [More]
Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

In a Sutter Institute of Medical Research study published this month in the Journal of Neurology, Neurosurgery, and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was found to reduce brain atrophy and cognitive decline in patients in the early, pre-dementia phase of Alzheimer's disease. [More]
OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy. [More]
Sexual activity causes physiological changes in the body that increase women's chances of getting pregnant

Sexual activity causes physiological changes in the body that increase women's chances of getting pregnant

Research from Indiana University has found that sexual activity triggers physiological changes in the body that increase a woman's chances of getting pregnant, even outside the window of ovulation. [More]
Serologic status and autoimmune cerebellar ataxia type predict treatment response

Serologic status and autoimmune cerebellar ataxia type predict treatment response

Patients with autoimmune cerebellar ataxia have better treatment responses and outcomes if they have the nonparaneoplastic form of the condition and are seropositive for neural plasma membrane protein or glutamic acid decarboxylase 65 antibodies, suggests research. [More]
New cell type appears to drive life-threatening food allergies

New cell type appears to drive life-threatening food allergies

Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not. [More]
Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb). [More]
Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler. [More]
TMIGD1 protein could be a novel target for restoring kidney function from kidney disease

TMIGD1 protein could be a novel target for restoring kidney function from kidney disease

A new discovery by Boston University School of Medicine (BUSM) researchers may change how kidney disease is treated in the future. [More]
Advertisement